Jupiter Neurosciences Inc (JUNS)

$JUNS I’m tired boss …

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ) announced participation in two upcoming Wall Street investor events the week of May 5, 2026. Founder, Chairman and CEO Christer Rosén will present at the Market Movers Investor Summit on Tuesday, May 5 at 9:00 AM ET (Track 2). The invitation-only summit, presented by The Money Channel NYC, runs May 4-5 in New York. Learn more: https://www.marketmoverssummit.com/ Jupiter will also participate in the D. Boral Capital 2026 Global Conference on Thursday, May 7 at The Plaza Hotel in New York, where management will hold one-on-one meetings with institutional investors across multiple sectors. Learn more: https://dboralcapital.com/conference/ Jupiter is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1 The company is developing therapies and consumer wellness products on its proprietary JOTROL micellar resveratrol delivery platform, with a Phase IIa Parkinson's trial and the Nugevia longevity and healthy aging consumer line. Jupiter is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marsh Hayward, Ph.D., Co-Founder and Chief Scientific Officer. Learn more at https://jupiterneurosciences.com. For investor inquiries: [email protected]. Discover more Featured Companies, Featured Experts, and Featured Conferences at https://b2idigital.com. David Shapiro, Chief Executive Officer of B2i Digital, is a personal shareholder of Jupiter Neurosciences. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$JUNS heads to the Market Movers Investor Summit on May 5, with CEO Christer Rosén speaking.

https://nfne.ws/295754 $JUNS #Energy #NASDAQ #Investing

$JUNS RSI: 52.40, MACD: -0.0089 Vol: 0.03, MA20: 0.40, MA50: 0.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ) Founder, Chairman and CEO Christer Rosén recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he addresses the commercial opportunity behind the Nugevia consumer product line. Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences.com and follow Jupiter on LinkedIn. "When it comes to the longevity and aging, that is exploding all over the world. And we think that this is something that can give us positive cash flow already next year," Rosen said, framing Nugevia as a consumer-facing cash flow generator that runs in parallel with the clinical pipeline. The commercial build-out behind that 2027 cash flow target includes: • A direct-to-consumer model operated through a small internal team and a global Miami-based agency rather than a direct sales force, keeping operating costs aligned with a small-cap structure. • Brand ambassadors including Anika Albrecht of the Latet Girls Tour and NBA Hall of Famer Chris Webber, broadening reach into sports and wellness audiences. • A compounding pharmacy network serving approximately 7,000 physicians as a potential B2B distribution channel that would layer onto the direct-to-consumer base. • A regulated positioning, which avoids claims of curing any disease, that differentiates Nugevia from many nutraceutical competitors that have faced FDA enforcement. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/nN6XL3_Q8aI Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marsh Hayward, Ph.D., Co-Founder and Chief Scientific Officer. For additional details, please visit the investor section of Jupiter's website at: https://jupiterneurosciences.com/investors/. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital. $INMB, $ANVS, $AVXL, $ATHA, $XBI

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ) Founder, Chairman and CEO Christer Rosén recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he walks investors through the structure of the company's lead clinical program. Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences.com and follow Jupiter on LinkedIn. Watch the clip here: https://youtube.com/shorts/RQwFxk1MlZg "It's led by Professor Charbel Moussa at Georgetown as the lead PI, and he has two MedStar centers that is also doing this with the best PIs you can have in Parkinson's because they believe that it's going to work. Relatively short study, 30 patients," Rosen explained, describing the trial design and the lead investigator's commitment to the program. A few design choices stand out in the Phase 2a protocol: • Primary endpoints are anchored in safety and pharmacokinetics, which Jupiter has already demonstrated in Phase 1. Secondary endpoints cover motor function, fall rates, and biomarkers including IL-6, neurofilament light, and TREM-2. • The 30-patient, placebo-controlled design is deliberately compact, supporting a shorter enrollment period and a top-line readout timed for the end of 2026. • The 200 mg and 400 mg arms sit well below the GI side effect threshold of approximately 1.5 to 2 grams per day associated with standard resveratrol. Jupiter's 9x bioavailability means therapeutic effect at a fraction of the dose. • A successful readout opens the door to strategic partnership discussions or NIA grant funding for follow-on indications such as Alzheimer's and mild cognitive impairment. Watch the full presentation, courtesy of Centri Business Consulting: https://youtu.be/nN6XL3_Q8aI Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marsh Hayward, Ph.D., Co-Founder and Chief Scientific Officer. For additional details, please visit the investor section of Jupiter's website at: https://jupiterneurosciences.com/investors/. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$JUNS Seriously what is wrong with this ?!!!

$JUNS Basura ! Piece of shit 💩

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ), a B2i Digital Featured Company, recently took part in the Virtual Investor Conferences Life Sciences Investor Forum. In the clip below, Founder, Chairman and CEO Christer Rosén discusses the company's two-track strategy combining a Parkinson's disease development program with a direct-to-consumer longevity business. Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 Watch the clip here: https://youtube.com/shorts/vp-f-HqQolw "I think in the US for a dual approach, some dual approach that we have, we both have the biotech side. And as you know, biotech is often smaller biotechs is zero or nothing. We obviously believe that we're going to be more towards the later part. And successful PD trial might trigger strategic partnership discussions and obviously that we believe with the data we get, that we get partnership on the mild cognitive impairment phase two trial. Obviously can trigger more than just a partnership, but we don't want to go that way yet, talk about that yet. We never planned to go out and take this all the way through phase three and be a commercial company to sell it ourselves to patients and so on. We're too small and it's too cumbersome to build that up... In summary, the dual approach keeps the high biotech exit possibility while the longevity DTC creates cash flow and maybe another exit there." In the full presentation, the company also discussed: • The 9x bioavailability breakthrough that underpins both the pharma and consumer programs • The Phase 2A trial timeline at Georgetown University and the path to top-line Parkinson's data • The Nugevia product line, brand ambassadors, and distribution channels including compounding pharmacies and wellness markets • The broader pipeline, including Alzheimer's, MCI, and rare disease opportunities that management believes could be pursued following positive Phase 2 data Watch the complete presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS) Founder, Chairman and CEO Christer Rosen recently presented at the Second Annual Centri Capital Conference at Nasdaq MarketSite, hosted by Centri Business Consulting. In this clip, he defines how Jupiter sits at the intersection of biotech clinical development and the longevity and aging market. Jupiter Neurosciences is a B2i Digital Featured Company (https://b2idigital.com/jupiter-neurosciences-1) developing therapies and consumer wellness products built on its proprietary JOTROL micellar resveratrol delivery platform. For more information, visit https://www.jupiterneurosciences.com and follow Jupiter on LinkedIn. "We really are a longevity biotech. So we are in the biotech space with a Parkinson's trial, but we also launched longevity and aging nutraceutical. And it's all based on how we started," Rosen explained, describing Jupiter's dual-path positioning as a clinical-stage developer with a parallel consumer commercialization track. A few reasons this dual-track story is important: • The traditional biotech path values a single binary clinical readout. Jupiter's structure layers a consumer revenue stream on top of that clinical optionality, which can reduce financing pressure during the trial period. • The longevity and healthy aging market is commercially active today, not dependent on a future FDA approval. Nugevia gives Jupiter access to that market while the Parkinson's program runs in parallel. • Both sides of the business rely on the same underlying JOTROL bioavailability work, so scientific validation in the clinical trial reinforces the consumer marketing case, and commercial traction on the consumer side helps support continued clinical investment. Watch the full presentation: https://youtu.be/nN6XL3_Q8aI Jupiter Neurosciences is led by Christer Rosen, Founder, Chairman and CEO; Alison D. Silva, President and Chief Business Officer; Saleem Elmasri, CPA, Chief Financial Officer; and Marshall Hayward, Ph.D., Co-Founder and Chief Scientific Officer. For additional details, please visit the investor section of Jupiter's website at: https://jupiterneurosciences.com/investors/. For investor inquiries, contact [email protected]. Content shared here is for general information only and is not an offer to buy or sell any security. Any securities-related activities by our personnel are conducted solely through an appropriately registered broker-dealer, separate from services provided by B2i Digital.

$JUNS Man this shit single handedly shit all over my portfolio 😢

$JUNS This turd is a lame ass stock !

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ), a B2i Digital Featured Company, recently presented at the Virtual Investor Conferences Life Sciences Investor Forum. In the clip below, President and CBO Alison Silva outlines the timeline for the company's Phase 2A Parkinson's disease study. View Clip Here: https://youtube.com/shorts/23IRp5Y6m_E Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 "Our trial timelines are rapidly accelerating at this point. We are just activating our sites. We expect to enroll the first patient and subsequently dose the first patient. I'd say in the next few weeks here -- it's always hard to tell exactly when it's going to happen, but we've made significant progress in 2026. Again, it's 30 subjects and three months of dosing. We expect pretty concurrent enrollment. So as soon as we get all subjects in, we'll report out on that. And then it's three months of dosing and then probably about a two-month readout at the end of last patient last dose. So we hope to be announcing top-line results early next year, about 12 months from now. If all goes according to plan, we're very e xcited to be able to use the data from this trial to build out the pipeline and also move into a larger phase 2B or 3 in Parkinson's." In the full presentation, the company also discussed: • The JOTROL platform's 9x bioavailability advantage and the IP protecting it through 2036 • The 30-patient Phase 2A trial design at Georgetown University, including the panel of up to 22 biomarkers being assessed • What positive data could mean for pharma partnering discussions and pipeline expansion into Alzheimer's and MCI • The Nugevia direct-to-consumer longevity line as a commercial complement to the Parkinson's program Watch the complete presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$JUNS We're on the same page now. $100 million that they can dilute at any moment—that's simply diabolical. This company has completely disappointed me.

$JUNS Man this garbage robbed me ! Manipulated as fuck 😢🤬

https://nfne.ws/292320 $JUNS #Energy #Banking #FinancialServices #NASDAQ #Investing

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ), a B2i Digital Featured Company, recently participated in the Virtual Investor Conferences Life Sciences Investor Forum. In the clip below, Founder, Chairman and CEO Christer Rosén explains why conventional resveratrol has limited therapeutic utility and what makes the company's patented JOTROL platform different. Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 "So when you look at what is the difference between resveratrol and JOTROL? With resveratrol, what [poor bioavailability] means is that when you swallow it, it's actually the liver that cleans out most of it, so you only get less than half of a percent goes into the bloodstream, and that is called the bioavailability. While we then had nine times higher bioavailability in our resveratrol trial, and that was an NIA-funded phase one study that through an IND with the FDA. And with regular resveratrol, there's no intellectual property. We have patents around the world through 2036. And resveratrol has very poor tolerability when it comes to GI when you take a higher dose. If it didn't have that problem, so you can take, for example, three grams of resveratrol, we wouldn't have much of a business. But reality is as soon as you go over about two grams a day, you're going to have severe stomach cramps and mostly sitting on the toilet. So we could show that with, in our phase one study, that with a 500 milligram dose in the JOTROL resveratrol preparation, we had very sufficient amount of resveratrol in the bloodstream, and that is really the key." In the full presentation, the company also discussed: • The Phase 1 bioavailability breakthrough and the academic collaborators it attracted • The Phase 2A Parkinson's trial design, enrollment status, and timeline to top-line data • The Nugevia consumer line and brand ambassador partnerships with Annika Sörenstam, Chris Webber, and Jean Fallacara • The pipeline of addi Watch the complete presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva , President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$JUNS 1$+ on deck

$JUNS added Kristopher Fishman and Sanjiv Lal to the Nugevia advisory board to deepen pharmacy and wellness-distribution expertise.

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ) is pleased to participate in the Second Annual Centri Capital Conference , taking place Tuesday, April 14, 2026, at Nasdaq ($NDAQ ) MarketSite in New York City. The Centri Capital Conference is a B2i Digital Featured Conference. See more details at: https://b2idigital.com/centri-capital-conference-2026 Jupiter Neurosciences, Inc. (NASDAQ: $JUNS) is a clinical-stage pharmaceutical company built around JOTROL, a patented resveratrol formulation that has demonstrated materially higher bioavailability than earlier versions of the compound. Based in Jupiter, Florida, the company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and central nervous system disorders while commercializing Nugevia, a premium longevity supplement line using the same delivery technology. On the pharmaceutical side, the FDA cleared the company's IND application in November 2025, authorizing a Phase 2A clinical trial in Parkinson's disease. The company is also exploring potential applications in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. Jupiter's consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging. Jupiter completed its IPO in December 2024 and is led by Christer Rosén, Founder, Chairman, and CEO. Building on a successful inaugural year, the Centri Capital Conference returns as a premier one-day event bringing together 500+ institutional investors, industry leaders, and executives from over 50 participating companies across healthcare, life sciences, technology, AI, digital assets, fintech, and other high-growth sectors. The full-day program features company presentations, fireside chats, curated one-on-one investor meetings, and a networking reception. B2i Digital is working closely with the Centri Business Consulting team, including Michael Aiello, Amanda Zeigler, Gerald Wik, Stephan Parico, Christopher Mora, Jaime Krug, Adam Batchelor, David Lawlor, and Dale Jones to enhance each presenter's reach through B2i Digital's network of 1.5M+ investors. The Centri Capital Conference is an invite-only event. For more information and to request registration, visit: https://www.meetmax.com/sched/event_130523/conference_register.html?attendee_role_id=CENTRI_INVESTOR Learn more about Jupiter Neurosciences, Inc. at https://b2idigital.com/jupiter-neurosciences-1?hsLang=en. Content is for informational purposes only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.